AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of AstraZeneca PLC (LON:AZN) have earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is £121.57 ($154.47).

Several equities research analysts recently issued reports on the company. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 28th. Jefferies Financial Group reaffirmed a “hold” rating and set a £113 ($143.58) price target on shares of AstraZeneca in a research report on Tuesday, May 21st. Berenberg Bank upped their price target on AstraZeneca from £130 ($165.18) to £150 ($190.60) and gave the company a “buy” rating in a research report on Friday, June 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a £110 ($139.77) price objective on shares of AstraZeneca in a report on Tuesday. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 21st.

AstraZeneca Price Performance

Shares of AZN opened at £124.16 ($157.76) on Wednesday. AstraZeneca has a 52-week low of GBX 9,461 ($120.22) and a 52-week high of £127.04 ($161.42). The company has a debt-to-equity ratio of 92.51, a quick ratio of 0.59 and a current ratio of 0.89. The business’s 50 day moving average price is £119.89 and its two-hundred day moving average price is £109.53. The firm has a market cap of £192.45 billion, a PE ratio of 3,979.49, a price-to-earnings-growth ratio of 0.97 and a beta of 0.16.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.